Drug
Olaparib
Olaparib: highest development phase Phase 3, developed by AstraZeneca, Sandoz. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AstraZeneca, Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| olaparib NCT04269200 | Phase 3 | Endometrial Neoplasms |
| Olaparib NCT02430311 | Phase 1 | Advanced Solid Tumours |
| Olaparib tablets, 150 mg NCT05258747 | Phase 1 | Ovarian Cancer |
Latest
No recent events.
Follow Olaparib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.